Kontrol Delivers Two BioCloud Units to Health Canada for Testing and Adds Middle East Distribution Partner

By AIT News Desk On May 31, 2021

Kontrol Technologies Corp. a leader in smart buildings and cities through IoT, Cloud and SaaS technology is pleased to announce that it has delivered two BioCloud units to Health Canada for testing and has added a Middle East distribution partner with regional exclusivity.

Testing with Health Canada

The two BioCloud units were delivered in May 2021 to Health Canada’s National Microbiology Level 4 laboratory. The testing is carried out at the request of several interested government agencies and at no cost to Kontrol. The testing is anticipated to include efficiencies and detection of SARs-COV-2 and its variants under various control conditions. Testing has commenced with results anticipated in July 2021.

Upon receipt of final testing and results the Company will announce and publish those results on its website, subject to any regulatory approval which may be required.

Tessl Raises $125 Million to build AI Native Software Development

Nov 15, 2024

Team-GPT Raises $4.5Million to Discover and Deploy AI Use Cases in Enterprises

Nov 15, 2024

Ironclad Launches Jurist: an AI-Powered Assistant That Shows its Work

Nov 15, 2024

Prev Next 1 of 40,388

New Distribution

Kontrol BioCloud has entered into an exclusive distribution agreement with the Royal Health Group, following a recent positive pilot completion as per the press release dated May 25^th, 2021. The Royal Health Group is led by Dr. Mohammed Al Seiari, a recognized health care leader in the United Arab Emirates (“UAE”). The Royal Health Group provides COVID-19 testing facilities and other health care services throughout the region.

“We are very impressed with the BioCloud technology,” said Dr. Mohammed Al Seiari. “The BioCloud technology can play an important role in supporting the detection of viruses and pathogens which can help provide the confidence we need to return to normal as the global economy seeks to re-open.”

Under the terms of the agreement Royal Health Group will have regional exclusivity for the UAE and the parties will negotiate the minimum number of annual units of BioCloud sales required to maintain the exclusivity. The exclusive period is for one year with an option to renew.

Kontrol BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).